Elevance Health EVP and CFO Mark Kaye sold 400 shares in the open market on Oct. 22, 2026, at $434.00 per share, for proceeds of about $173.60K. The filing indicates the sale was not made under a pre-scheduled Rule 10b5-1 trading plan, which can make the timing more noteworthy than routine, automated selling—though executives sell for many personal reasons that aren’t tied to company performance. This trade matters because a CFO is one of the most senior officers responsible for financial reporting, capital allocation, and communicating results to investors, so their transactions often draw attention. That said, the size of this sale is relatively modest in dollar terms and, by itself, doesn’t establish a clear message about the business. Looking at recent activity, this is the only reported insider trade at ELV in the last 30 days, so there isn’t a pattern of repeated selling by Kaye during this period. Prior insider purchases by other executives, including the CEO, add context that insider sentiment has not been uniformly one-directional, leaving a mixed picture based on available filings.